Given our observations of near-mutual exclusivity of cohesin and TP53 mutations (Figs. 2 and 3A), and the well-established association of TP53 mutations with poor outcomes [38, 39], we next compared the OS and AML-free survival of patients with STAG2-mutant MDS to TP53-mutant MDS and cohesin/TP53-WT MDS. This evidence concerns the gene STAG2 and myelodysplastic syndrome.